



# HEALTH INFORMATION *designs*



**West Virginia  
Department of Health and Human  
Resources**

**Bureau for Medical Services  
Drug Utilization Review Board**

November 15, 2017

## Second Quarter 2017

- **Profiles Reviewed: 1,206**
- **Cases Identified: 900**
- **Letters Mailed**
  - **Prescribers: 1,105**
  - **Pharmacies: 971**
- **Responses**
  - **Prescribers: 179 (16%)**
  - **Pharmacies: 174 (18%)**

## Third Quarter 2017

- **Profiles Reviewed: 1,232**
- **Cases Identified: 1,087**
- **Letters Mailed**
  - **Prescribers: 1,319**
  - **Pharmacies: 1,163**
- **Responses**
  - **Prescribers: 221 (17%)**
  - **Pharmacies: 211 (18%)**



# Third Quarter 2017: Lock-In (LI)

| Quarter)                        | 3 <sup>rd</sup> Quarter | (2 <sup>nd</sup> |
|---------------------------------|-------------------------|------------------|
| • Profiles Reviewed:            | 177                     | (152)            |
| • Total Cases:                  | 110                     | (53)             |
| • Case Rate:                    | 62%                     | (35%)            |
| • Warning Cases:<br>(47)        | 65                      |                  |
| • Initial LI Cases:<br>(4)      | 12                      |                  |
| • Cases Continued in LI:<br>(2) | 18                      |                  |



# Third Quarter 2017: July RDUR Criteria

- **Controlled substances**
- **Drug-Disease Interactions**
  - Increased seizure risk
  - Increased QT prolongation risk
  - Increased cardiometabolic effects of atypical antipsychotics
- **Drug-Drug Conflicts:**
  - Aripiprazole with CYP 3A4 inducers and inhibitors
  - Haloperidol with CYP 3A4 and 2D6 inhibitors
  - Clozaril with various CYP inducers and inhibitors
  - Brexpiprazole with potent CYP 2D6 inhibitors
- **Overutilization**
  - High pediatric dose of antipsychotics
  - Overutilization of antipsychotics
- **Non-Compliance**
  - Underutilization of antipsychotic therapy
- **Clinical Appropriateness**
  - Atypical antipsychotic metabolic effects
  - Polypsychopharmacy



# Third Quarter 2017: August RDUR Criteria

- **Controlled substances**
- **Drug-Drug Conflicts:**
  - Increased risk of serotonin syndrome
    - TCAs with cyclobenzaprine
    - SSRI's with triptans
- **Overutilization**
  - Over 100 mg morphine equivalents per day
- **Clinical Appropriateness**
  - Multiple oral anti-diabetic medications without insulin therapy



# Third Quarter 2017: September RDUR Criteria

- **Controlled substances**
- **Drug-Disease Interactions**
  - NSAIDs in patients with heart disease/risk factors
- **Drug-Drug Conflicts:**
  - High dose simvastatin with verapamil
  - Oxycodone with CYP 2D6 inhibitors
  - Tamsulosin with CYP 2D6 and 3A4 inhibitors
- **Non-Compliance**
  - Underutilization of lipid lowering agents
- **Clinical Appropriateness**
  - NSAIDs for elderly patients
  - Sedative hypnotics in patients with alcohol use diagnoses
  - Sertraline for OCD in pediatric patients



# Third Quarter 2017

## September Targeted Intervention:

- **Jardiance became preferred SGLT2 inhibitor on October 1, 2017.**
- **Identify patients on, and prescribers of, non-formulary SGLT2 inhibitors**
  - **Letter sent to prescribers with patients on any SGLT2 inhibitor other than Jardiance to inform them of the change.**
    - Single letter to prescriber with all patients affected.
  - **Letters sent to providers included all affected patients.**
    - Cases Reviewed: 338
    - Letters Sent: 250



# Third Quarter 2017

## September Educational Intervention:

- **Duplication of Sedating Medications**
  - **Patients on a long-acting benzodiazepine and a sedative hypnotic**
    - Clonazepam, diazepam, flurazepam, chlordiazepoxide
    - Hetlioz, zolpidem, zaleplon, chloral hydrate, Rozerem, eszopiclone, Sllenor, triazolam, temazepam, quazepam, and estazolam
  - **Education on risk of increased CNS depression, sedation and abuse/dependence**
  - **Letter sent to all prescribers of at least one of the above for patients with concurrent or alternating claims for the combination**
    - Cases Reviewed: 435
    - Letters Sent: 249



# Third Quarter 2017

## Proposed Educational Interventions

- **New preferred diabetic testing supplies information**
  - **MD letters for patients using diabetic testing supplies**
- **Smoking cessation counseling information for physicians**
  - **MD letters for those that prescribe tobacco cessation products**



# Distribution of Cases

|                                  | 3 <sup>rd</sup> Quarter 2017 |     | 2 <sup>nd</sup> Quarter 2017 |
|----------------------------------|------------------------------|-----|------------------------------|
| <b>Drug-Disease Interactions</b> | 33                           | 3%  | 12%                          |
| <b>Drug-Drug Conflict</b>        | 423                          | 39% | 61%                          |
| <b>Over-utilization</b>          | 314                          | 29% | 8%                           |
| <b>Non-compliance</b>            | 52                           | 5%  | 6%                           |
| <b>Clinical Appropriateness</b>  | 265                          | 24% | 12%                          |

- **Drug-Disease Interactions:** Patients receiving a drug that may worsen or precipitate a medical condition.
- **Drug-Drug Conflict:** Patients receiving two or more drugs that may interact and produce unpredictable and undesirable effects.
- **Over-utilization:** Patients taking medications in apparently excessive doses or for excessive lengths of time.
- **Non-compliance:** Patients not taking medication according to directions, resulting in possible sub-therapeutic response.
- **Clinical Appropriateness:** Patients who are taking medications for treatment of a disease for which the medication is not standard of care.



# 3<sup>rd</sup> Quarter 2017: Evaluation Responses

|                             | <b>2<sup>nd</sup> Quarter<br/>2017</b> | <b>3<sup>rd</sup> Quarter<br/>2017</b> |
|-----------------------------|----------------------------------------|----------------------------------------|
| <b>Extremely<br/>Useful</b> | 27                                     | 29 (↑)                                 |
| <b>Useful</b>               | 61                                     | 54 (↓)                                 |
| <b>Somewhat<br/>Useful</b>  | 24                                     | 31 (↑)                                 |
| <b>Neutral</b>              | 10                                     | 26 (↑)                                 |
| <b>Not useful</b>           | 21                                     | 22 (↑)                                 |



---

# *Questions?*

